Liquidia Showcases Promising Pulmonary Hypertension Research

Exciting Research Advancements in Pulmonary Hypertension

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical leader dedicated to developing innovative therapies for rare cardiopulmonary diseases, has announced a significant presence at the upcoming Pulmonary Hypertension Professional Association (PHPN) Symposium. This prestigious event will take place from September 18 to September 20, where Liquidia plans to showcase four important posters highlighting their latest research efforts.

Live Thematic Poster Presentations

During a live thematic poster session, Liquidia intends to share groundbreaking safety and exploratory efficacy data from their ASCENT study involving LIQ861 (now known as YUTREPIA™). The presentation will particularly focus on the outcomes for patients experiencing pulmonary hypertension associated with interstitial lung disease (PH-ILD) through Week 8 of the study.

Insights from the ASCENT Study

Liquidia's ASCENT study emphasizes the importance of thorough safety checks and exploratory efficacy data. YUTREPIA™ is designed to address the challenges faced by PH-ILD patients, and this session aims to provide invaluable insights from participant responses. These findings are integral to understanding how YUTREPIA™ can enhance patient care and treatment outcomes.

Prior Research Highlights

In addition to the new data, three previously published posters will also be presented. These posters delve into YUTREPIA’s positive impact on cardiac effort, the overall quality of life for patients, and insights into patient device use. Each of these topics is critical in showcasing the comprehensive benefits of this innovative treatment option.

Discussion Sessions at the Symposium

The posters will be shared during dedicated sessions on September 19, providing an opportunity for in-depth discussions among peers in the field. Here are the details for the presentations:

• Poster Session: Poster Board #1037
  Abstract: A Continued ASCENT to Week 8: Initial Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients
• Poster Session: Poster Board #1041
  Abstract: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from the ASCENT Trial
• Poster Session: Poster Board #1051
  Abstract: Quality of Life (QOL) in PAH Patients Receiving an Inhaled Dry Powder Treprostinil (LIQ861) in the INSPIRE Study
• Poster Session: Poster Board #1053
  Abstract: Robustness of LIQ861, a Dry-Powder Inhaled Formulation of Treprostinil, in Patient Misuse Scenarios

Understanding YUTREPIA™

YUTREPIA is a groundbreaking inhaled dry-powder formulation of treprostinil. It's delivered through an easy-to-use, compact device that requires minimal effort. The drug is specifically indicated for treating pulmonary arterial hypertension (PAH) and PH-ILD, aiming to enhance exercise capabilities for those affected.

Innovative Technology Behind YUTREPIA™

Liquidia utilizes its proprietary PRINT technology to create uniform drug particles, which ensures effective deposition in the lungs for maximal therapeutic benefit. This innovative approach not only improves patient outcomes but transforms how treatments for pulmonary hypertension are delivered.

About Liquidia Corporation

Liquidia Corporation is committed to developing innovative therapies aimed at improving the quality of life for patients suffering from rare cardiopulmonary conditions. Their ongoing projects include the commercialization of YUTREPIA™ and the development of L606, an investigational sustained-release formulation of treprostinil, which is expected to offer benefits with a convenient dosage regimen. Currently, Liquidia also markets a generic Treprostinil Injection, continuing to expand its portfolio to better serve the needs of patients with pulmonary hypertension.

Frequently Asked Questions

1. What is YUTREPIA™?

YUTREPIA™ is an inhaled dry-powder formulation of treprostinil designed for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

2. When will Liquidia present its research?

Liquidia will present its research at the PHPN Symposium on September 19, during a thematic poster session.

3. How does YUTREPIA™ improve patient's quality of life?

YUTREPIA™ is designed to enhance exercise capability and reduce symptoms associated with pulmonary hypertension, thereby improving overall quality of life for patients.

4. What technology does Liquidia use for drug formulation?

Liquidia employs its PRINT technology to create precise and uniform particles for effective drug delivery to the lungs.

5. Who can I contact for more information about Liquidia?

For investor inquiries, reach out to Jason Adair at 919.328.4350 or jason.adair@liquidia.com. For media inquiries, contact Patrick Wallace at 919.328.4383 or patrick.wallace@liquidia.com.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.